- Home
- APM vs PRTG Comparison
APM vs PRTG Comparison
Compare APM & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- PRTG
- Stock Information
- Founded
- APM 2010
- PRTG 1973
- Country
- APM United Kingdom
- PRTG British Virgin Islands
- Employees
- APM N/A
- PRTG N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- PRTG Oil & Gas Production
- Sector
- APM Health Care
- PRTG Energy
- Exchange
- APM Nasdaq
- PRTG Nasdaq
- Market Cap
- APM 4.0M
- PRTG 4.7M
- IPO Year
- APM 2018
- PRTG N/A
- Fundamental
- Price
- APM $0.74
- PRTG $8.60
- Analyst Decision
- APM
- PRTG Hold
- Analyst Count
- APM 0
- PRTG 1
- Target Price
- APM N/A
- PRTG N/A
- AVG Volume (30 Days)
- APM 69.7K
- PRTG 1.8M
- Earning Date
- APM 12-27-2024
- PRTG 11-26-2024
- Dividend Yield
- APM N/A
- PRTG N/A
- EPS Growth
- APM N/A
- PRTG N/A
- EPS
- APM N/A
- PRTG N/A
- Revenue
- APM $431,378.00
- PRTG N/A
- Revenue This Year
- APM $157,729.10
- PRTG N/A
- Revenue Next Year
- APM N/A
- PRTG N/A
- P/E Ratio
- APM N/A
- PRTG N/A
- Revenue Growth
- APM N/A
- PRTG N/A
- 52 Week Low
- APM $0.46
- PRTG $2.10
- 52 Week High
- APM $17.49
- PRTG $40.80
- Technical
- Relative Strength Index (RSI)
- APM 41.12
- PRTG 65.98
- Support Level
- APM $0.73
- PRTG $2.95
- Resistance Level
- APM $0.78
- PRTG $12.89
- Average True Range (ATR)
- APM 0.09
- PRTG 0.89
- MACD
- APM 0.04
- PRTG 0.44
- Stochastic Oscillator
- APM 64.47
- PRTG 46.88
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.